Genelux Corporation (NASDAQ: GNLX) is a Healthcare company (Biotechnology) with a market capitalization of $90M. The Maz Rating grades it against the other companies in its sector.
Genelux Corporation's current Maz Rating and its five factor grades are for members: log in to see them.
At $2.00, Genelux Corporation trades at 11141.7x sales and 9.7x book value. Over the last twelve months it generated about $8122 of revenue and a net loss of $42M. It runs a gross margin of -2975.0%, an operating margin of -472737.5% and a net margin of -451600.0%. It shows return on equity of -241.8%, return on invested capital of -328.2% and a free cash flow yield of -33.1%. On the balance sheet: a debt-to-equity ratio of 0.26 and a current ratio of 1.16. Over the past 52 weeks the share price ranged from $1.77 to $5.89, with a beta of 0.58.
Genelux Corporation does not currently pay a dividend.
3 Wall Street analyst ratings cover the stock: 2 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.